A Prospective, Multi-Center PRostate Cancer Individual Signature Evaluation Trial (PReCISE) in Patients Undergoing Scheduled Prostate Biopsy
Observational
Observational Model: Case Control, Time Perspective: Prospective
ability of whole blood gene expression to predict biopsy outcome
pre-biopsy
No
William Oh, MD
Principal Investigator
Mt. Sinai School of Medicine
United States: Institutional Review Board
PReCISE
NCT00966095
December 2009
Name | Location |
---|---|
University of Michigan | Ann Arbor, Michigan 48109-0624 |
Mayo Clinic | Rochester, Minnesota 55905 |
Beth Israel Deaconess Medical Center | Boston, Massachusetts 02215 |
Mount Sinai Medical Center | New York, New York 10029 |
Urology San Antonio Research | San Antonio, Texas 78229 |
Urology Clinics of North Texas | Dallas, Texas 75231 |
Duke University Medical Center | Durham, North Carolina 27710 |
University of Chicago Medical Center | Chicago, Illinois 60637 |
San Bernardino Urological Associates | San Bernardino, California |
Karmanos Cancer Institute Wayne State University | Detroit, Michigan 48201 |
Durham VA Medical Center | Durham, North Carolina 27705 |
University Urology Associates | New York, New York 10016 |
The Urology Center of Colorado | Denver, Colorado 80211 |
Johns Hopkins University Brady Urological Institute | Baltimore, Maryland 21287 |
Brigham and Women's Hospital/ Dana Farber Cancer Institute | Boston, Massachusetts 02115 |
Bay State Clinical Trials | Watertown, Massachusetts 02472 |
University of Washington Department of Urology | Seattle, Washington 98195 |